2017 Fiscal Year Final Research Report
Anti-inflammatory effects of Novel NF-kB inhibitor, DHMEQ on in vitro and in vivo model of ocular inflammation
| Project/Area Number |
15K10901
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Kyorin University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Nakayama Makiko 杏林大学, 医学部, 助教 (30736278)
Keino Hiroshi 杏林大学, 医学部, 准教授 (90328211)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 眼炎症 |
|---|
| Outline of Final Research Achievements |
Dehydroxymethylepoxyquinomicin (DHMEQ) is a novel nuclear factor (NF)-kB inhibitor. We investigated whether DHMEQ can modulate the proinflammatory cytokine induced expression of intracellular adhesion molecule (ICAM)-1 and chemokines in a human retinal pigment epithelial (RPE) cell line (ARPE-19). In addition, we investigated whether intravitreal injection of DHMEQ was effective for suppression of experimental autoimmune uveoretinitis (EAU). DHMEQ effectively down-regulated the expression of ICAM-1 in TNF-alpha stimulated ARPE-19 cells. Furthermore, DHMEQ suppressed the production of both IL-8 and MCP-1. However, there was no significant difference in EAU clinical score between control eyes and DHMEQ-treated eyes in EAU-induced rats. These results suggest that DHMEQ may play a role in reducing ICAM-1 and chemokine mediated inflammatory disorders in the eye, however further study is warranted for clinical application of DHMEQ for autoimmune uveitis.
|
| Free Research Field |
眼科学
|
